Prevention of Osteoporosis in Men With Prostate Cancer

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this two year study is to examine the safety and effectiveness of alendronate (Fosamax) for the prevention of bone loss in men with prostate cancer who are on therapy to lower their testosterone levels. All men will receive appropriate calcium and vitamin D supplements and one to two years of alendronate therapy. Bone density tests will be done every six months.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Alendronate

Criteria

Inclusion Criteria:

• Men age 50-85

• Stage D0 prostate cancer

• On androgen deprivation therapy

Exclusion Criteria:

• Renal failure

• Hyperthyroidism

• Cushing's syndrome

• Metabolic bone disease

• Use of glucocorticoids

• Use of certain anticonvulsants

• On osteoporosis therapies

• Nonprostate cancers